Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

By T. Force, D. Krause, R. A. Etten. Nature Reviews. Cancer, 2007

805 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/16f0d2e14e1805fa891f514fd8a475bfe23dfec6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Molecular Biology

Citations in the corpus

Combining Machine Learning Systems and Multiple Docking Simulation Packages to Improve Docking Prediction Reliability for Network Pharmacology (2013, background): “Its unanticipated inhibition of members of the ribosomal S6 kinase (RSK) and AMP-activated protein kinase (AMPK) families are at least partly responsible for the drug’s cardiotoxicity [3].”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “5).(67,68) The prognosis of patients experiencing cardiotoxicity with these drugs is difficult to assess accurately, as most of these compounds are used in patients with metastatic disease with limited life expectancy.”
Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. (2010, background): “The vast majority of kinase inhibitor development is in the cancer field (128), and that is the case with ERK inhibitors (2, 281, 344).”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “5).(67,68) The prognosis of patients experiencing cardiotoxicity with these drugs is difficult to assess accurately, as most of these compounds are used in patients with metastatic disease with limited life expectancy.”
Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, background): “(43) suggest that sunitinib may cause ardiotoxicity through inhibition of ribosomal S6 kinase, eading to the activation of the intrinsic apoptotic pathway nd ATP depletion.”
The safety and side effects of monoclonal antibodies (2010, background): “pdf">trastuzumab in clinical trials was that of cardiotoxicit”